US EditionPublished • loading... • Updated
IL lawmakers push discount drug legislation to prevent restricted access
Illinois lawmakers seek to protect access to discounted medicines for low-income and vulnerable patients by banning restrictions on the 340B program, which has bipartisan support.
- On Feb. 17, the Illinois House faces a concurrence vote on a Senate Amendment to House Bill 2371 that would block restrictions on the federal 340B program after unanimous approvals.
- State Rep. Anna Moeller, D-Elgin, said Senate Amendment No. to House Bill 2371 would prevent manufacturers from imposing limits that hurt providers delivering discounted medication to low-income families, seniors and patients with chronic conditions.
- Speaking at a rally in Chicago on Sunday, U.S. Rep. Danny Davis urged Illinois House Speaker Emanuel "Chris" Welch to call the bill, while State Rep. La Shawn Ford also pushed Welch to support State Rep. Anna Moeller's legislation.
- Supporters counter that programs like 340B `cost taxpayers nothing`, while Tom Wilbur, PhRMA Deputy Vice President, said critics see the program as exploited by hospitals and called for federal solutions.
- With the House next meeting Feb. 17, supporters press Speaker Welch to call the bill, which has bipartisan support and unanimous committee approval.
Insights by Ground AI
13 Articles
13 Articles
IL lawmakers push discount drug legislation to prevent restricted access - Regional Media News
(The Center Square) - Illinois lawmakers are pushing an amendment to ban restrictions or interference with a federal discount drug program. Speaking at a rally in Chicago on Sunday, state Rep. Anna Moeller, D-Elgin, said access to affordable medication is a lifeline, not a luxury. "The 340B program is one of the most important tools that we have to keep medications affordable for low-income families, seniors and patients with chronic conditions,…
Coverage Details
Total News Sources13
Leaning Left1Leaning Right3Center4Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
13%
C 50%
R 37%
Factuality
To view factuality data please Upgrade to Premium
